Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) had its price objective upped by equities researchers at HC Wainwright from $12.00 to $18.00 in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 152.45% from the company’s current price.

A number of other equities research analysts have also issued reports on GLMD. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Wednesday, August 2nd. Maxim Group reaffirmed a “buy” rating and set a $14.00 price objective (up from $9.00) on shares of Galmed Pharmaceuticals in a report on Monday, July 31st. Finally, ValuEngine raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 17th.

Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 7.13 on Tuesday. The firm has a 50-day moving average of $6.63 and a 200-day moving average of $5.22. Galmed Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $8.60. The stock’s market cap is $87.12 million.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The business had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.29 million. Analysts expect that Galmed Pharmaceuticals will post ($0.95) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/galmed-pharmaceuticals-ltd-glmd-price-target-increased-to-18-00-by-analysts-at-hc-wainwright.html.

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. KCG Holdings Inc. bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent 13F filing with the SEC. The fund bought 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned about 0.17% of Galmed Pharmaceuticals at the end of the most recent reporting period. 7.99% of the stock is currently owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.